https://orcid.org/0000-0001-5961-9228Dr. Wither’s translational research program is focused on identifying the genetic and immune system abnormalities that lead to systemic autoimmune rheumatic diseases (SARD), including systemic lupus erythematosus, Sjogren’s disease and scleroderma.
The goals of her program are the following:
1) to identify biomarkers for the early identification of patients at risk for developing SARD;
2) to evaluate therapies for prevention of SARD;
3) to characterize the immune mechanisms that lead to disease flare/progression; this information will improve diagnosis of complications and tailoring of treatments to each patient's disease; and
4) to develop diagnostic tests using novel biomarkers to monitor progression and severity of SARD complications (eg, renal disease in systemic lupus erythematosus) and response to therapy.
The goals of her program are the following:
1) to identify biomarkers for the early identification of patients at risk for developing SARD;
2) to evaluate therapies for prevention of SARD;
3) to characterize the immune mechanisms that lead to disease flare/progression; this information will improve diagnosis of complications and tailoring of treatments to each patient's disease; and
4) to develop diagnostic tests using novel biomarkers to monitor progression and severity of SARD complications (eg, renal disease in systemic lupus erythematosus) and response to therapy.